Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

“This collaboration represents a meaningful step toward realizing the therapeutic potential of bispecific and trispecific ADCs,” said Roland Green, CEO of Invenra